Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 10/20 | 0.46 |
| ▸ | DRD2 | P14416 | 9/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 6/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | TOP1 | P11387 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475234 | 1.00 | DRD3 (0.46) | DRD3DRD2PDE3BPDE3AP2RY12 | |
| SCHEMBL6474089 | 0.94 | DRD3 (0.43) | DRD3DRD2PDE3BPDE3AP2RY12 | |
| SCHEMBL6474086 | 0.94 | DRD3 (0.43) | DRD3DRD2PDE3BPDE3AP2RY12 | |
| SCHEMBL6481891 | 0.93 | PDE3B (0.48) | DRD3DRD2PDE3BPDE3AP2RY12 | |
| SCHEMBL6481888 | 0.93 | PDE3B (0.48) | DRD3DRD2PDE3BPDE3AP2RY12 | |
| SCHEMBL6475201 | 0.91 | PPARA (0.50) | DRD3DRD2PDE3BPDE3AP2RY12 | |
| SCHEMBL6475198 | 0.91 | PPARA (0.50) | DRD3DRD2PDE3BPDE3AP2RY12 | |
| SCHEMBL6482133 | 0.88 | KDM4E (0.51) | DRD3DRD2PDE3BPDE3AP2RY12 | |
| SCHEMBL6482841 | 0.85 | GAA (0.51) | PDE3BPDE3AP2RY12PDE2ALTB4R | |
| SCHEMBL6482127 | 0.84 | PTGER4 (0.49) | DRD3DRD2PDE3BPDE3AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855714-B2 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-15 | — | — | US | claimed |
| EP-1404321-A1 | 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | Schering Aktiengesellschaft (DE) | 2004-04-07 | — | — | EP | claimed |
| US-20030055057-A1 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-03-20 | — | — | US | claimed |
| WO-2003004023-A1 | 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-16 | — | — | WO | claimed |
| US-6855714-B2 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055057-A1 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives | ARG2, MSR1, ARG1 | DRD3 405/4885DRD2 521/4885PDE3B 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.